CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY INFORMATION

CentraState Healthcare System, Inc. Years Ended December 31, 2019 and 2018 With Report of Independent Auditors

Ernst & Young LLP



Consolidated Financial Statements and Supplementary Information

Years Ended December 31, 2019 and 2018

Contents

Report of Independent Auditors	
Consolidated Financial Statements	
Consolidated Balance Sheets	3
Consolidated Statements of Operations	4
Consolidated Statements of Changes in Net Assets	5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7
Supplementary Information	
Consolidating Balance Sheet	44
Consolidating Statement of Operations	46
Consolidating Statement of Changes in Net Assets	



Ernst & Young LLP 99 Wood Avenue South Metropark P.O. Box 751 Iselin, NJ 08830-0471 Tel: +1 732 516 4200 Fax: +1 732 516 4429

ev.com

Report of Independent Auditors

The Board of Trustees CentraState Healthcare System, Inc.

We have audited the accompanying consolidated financial statements of CentraState Healthcare System, Inc. (the System), which comprise the consolidated balance sheets as of December 31, 2019 and 2018, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of CentraState Healthcare System, Inc. at December 31, 2019 and 2018, and the consolidated results of its operations, changes in its net assets and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

Adoption of ASU No. 2016-02, Leases

As discussed in Note 1 to the consolidated financial statements, the System changed its method of accounting for leases as a result of the adoption of the amendments to the Financial Accounting Standards Board Accounting Standards Codification resulting from Accounting Standards Update No. 2016-02, *Leases*, effective January 1, 2019. Our opinion is not modified with respect to this matter.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying consolidating financial statements as of and for the year ended December 31, 2019 are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audits of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Ernst + Young LLP

April 15, 2020

Consolidated Balance Sheets

1988 2018 Assets Cash and cash equivalents 1888 1898 1808 <th c<="" th=""><th></th><th colspan="5">December 31</th></th>	<th></th> <th colspan="5">December 31</th>		December 31				
Assets Current assets: \$ 18,824 \$ 24,098 Cash and cash equivalents \$ 164,923 150,625 Assets limited as to use that are required for current liabilities (Note 4) 1,094 1,036 Patient accounts receivable, net 28,865 26,349 Other current assets 19,539 11,663 Total current assets 233,245 213,771 Assets limited as to use – noncurrent (Note 4) 29,387 28,207 Property, plant, and equipment, net (Note 6) 194,120 189,613 Operating lease assets (Note 8) 13,983 – Noncurrent assets (Note 5) 13,583 3,428 Current liabilities 13,583 3,428 Current maturities of long-term debt and finance lease obligations (Note 7) \$ 6,825 \$ 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 – Current dobt and finance lease obligations, excluding current maturities (Note 7) 1112,230 118,							
Current assets: \$ 18,824 \$ 24,098 Short-term investments (Note 4) 164,923 150,625 Assets limited as to use that are required for current liabilities (Note 4) 1,094 1,036 Patient accounts receivable, net Other current assets 23,3245 26,349 Other current assets 233,245 213,771 Assets limited as to use – noncurrent (Note 4) 29,387 28,207 Property, plant, and equipment, net (Note 6) 194,120 189,613 Operating lease assets (Note 8) 13,983 - Noncurrent assets (Note 5) 13,583 3,242 Extinibilities and net assets 13,583 3,242 Current liabilities 5,682 6,635 Current maturities of long-term debt and finance lease obligations (Note 7) 5,682 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 12,87 Operating lease liability – current (Note 8) 1,118 - Other current liabilities 53,922 46,729 Professional liability insurance and other no			(In The	ousar	ıds)		
Cash and cash equivalents \$ 18,824 \$ 24,098 Short-term investments (Note 4) 164,923 150,625 Assets limited as to use that are required for current liabilities (Note 4) 1,094 1,036 Patient accounts receivable, net 28,865 26,349 Other current assets 19,539 11,663 Total current assets 233,245 213,771 Assets limited as to use – noncurrent (Note 4) 29,387 28,207 Property, plant, and equipment, net (Note 6) 194,120 189,613 Operating lease assets (Note 8) 13,983 — Noncurrent assets (Note 5) 13,583 3,428 Every think and net assets 13,583 3,428 Current liabilities 5 6,825 6,635 Current maturities of long-term debt and finance lease obligations (Note 7) \$ 6,825 \$ 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 — Total current liabilities <td< td=""><td>Assets</td><td></td><td></td><td></td><td></td></td<>	Assets						
Short-term investments (Note 4) 164,923 150,625 Assets limited as to use that are required for current liabilities (Note 4) 1,094 1,036 Patient accounts receivable, net 28,865 26,349 Other current assets 19,539 11,663 Total current assets 29,387 28,207 Assets limited as to use – noncurrent (Note 4) 29,387 28,207 Property, plant, and equipment, net (Note 6) 194,120 189,613 Operating lease assets (Note 8) 13,983 – Noncurrent assets (Note 5) 13,583 3,428 Extractional net assets 484,318 \$ 435,019 Current liabilities 5 483,019 Extractional net assets 8 6,825 \$ 6,835 Current maturities of long-term debt and finance lease obligations (Note 7) \$ 6,825 \$ 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 — 7 Cong-term debt and finance lease obligations, ex	Current assets:						
Assets limited as to use that are required for current liabilities (Note 4)		\$		\$			
Itabilities (Note 4) 1,094 1,036 Patient accounts receivable, net 28,865 26,349 Other current assets 19,539 11,663 Total current assets 233,245 213,771 Assets limited as to use – noncurrent (Note 4) 29,387 28,207 Property, plant, and equipment, net (Note 6) 194,120 189,613 Operating lease assets (Note 8) 13,983 - Noncurrent assets (Note 5) 13,583 3,428 Current liabilities 848,318 \$ 35,019 Current liabilities Current maturities of long-term debt and finance lease 86,825 \$ 6,635 Current maturities of long-term debt and finance lease 41,906 38,487 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 16,618 - Total current liabilities 338 320 Total current liabilities 5,697 7,736 Forbessional liability insurance and other noncurrent (Note 3) 2,727<			164,923		150,625		
Patient accounts receivable, net Other current assets 28,865 (19,539) 26,349 (19,638) Total current assets 233,245 213,771 Assets limited as to use – noncurrent (Note 4) 29,387 (28,207) Property, plant, and equipment, net (Note 6) 194,120 (189,613) Operating lease assets (Note 8) 13,983 (3,428) Noncurrent assets (Note 5) 13,583 (3,428) Current liabilities 8484,318 (3,5019) Current maturities of long-term debt and finance lease obligations (Note 7) \$6,825 (8,635) 6,635 Accounts payable and accrued expenses 41,906 (38,487) 33,435 1,287 Operating lease liability – current (Note 8) 3,235 (1,287) 1,287 Operating lease liability – current (Note 8) 3,335 (1,287) 1,287 Operating lease liabilities (Note 7) 1112,230 (118,985) 118,985 Professional liability insurance and other noncurrent liabilities (Note 9) 5,597 (7,736) Estimated third-party payor settlements – noncurrent (Note 3) 2,727 (3,069) Operating lease liability – noncurrent (Note 8) 112,365 (7,736) Professional liability insurance and other noncurrent (Note 3) 2,727 (3,069) <td< td=""><td>•</td><td></td><td></td><td></td><td></td></td<>	•						
Other current assets 19,539 11,663 Total current assets 233,245 213,771 Assets limited as to use – noncurrent (Note 4) 29,387 28,207 Property, plant, and equipment, net (Note 6) 194,120 189,613 Operating lease assets (Note 8) 13,583 - Noncurrent assets (Note 5) 13,583 3,242 Exhibitities and net assets 3,248 \$484,318 \$45,019 Current liabilities S 484,318 \$45,019 Current maturities of long-term debt and finance lease obligations (Note 7) \$6,635 \$6,635 \$6,635 Accounts payable and accrued expenses 41,906 38,487 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 16,635 46,729 Total current liabilities 53,922 46,729 Forfers from debt and finance lease obligations, excluding current maturities (Note 7) 1112,230 118,985 Forfers from the debt and finance lease obligations, excluding current maturities (Note 7) 7,736 5,697 7,736 <t< td=""><td></td><td></td><td></td><td></td><td>,</td></t<>					,		
Total current assets 233,245 213,771 Assets limited as to use – noncurrent (Note 4) 29,387 28,207 Property, plant, and equipment, net (Note 6) 194,120 189,613 Operating lease assets (Note 8) 13,983 – Noncurrent assets (Note 5) 13,583 3,428 Example 1 484,318 3,428 Current liabilities 5 484,318 3,428 Current maturities of long-term debt and finance lease obligations (Note 7) \$6,825 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 – Other current liabilities 338 320 Total current liabilities (Note 7) 112,230 118,985 Professional liability insurance and other noncurrent liabilities (Note 9) 5,697 7,736 Estimated third-party payor settlements – noncurrent (Note 3) 2,727 3,069 Poeferred revenue and refundable advance fees 47,090 46,428 Total liabiliti							
Assets limited as to use – noncurrent (Note 4) 29,387 28,207 Property, plant, and equipment, net (Note 6) 194,120 189,613 Operating lease assets (Note 8) 13,983 – Noncurrent assets (Note 5) 13,583 3,428 Example of the second of the	Other current assets						
Property, plant, and equipment, net (Note 8) 194,120 189,613 Operating lease assets (Note 8) 13,983 — Noncurrent assets (Note 5) 13,583 3,428 \$ 484,318 \$ 435,019 Liabilities and net assets Current liabilities: Current maturities of long-term debt and finance lease obligations (Note 7) \$ 6,825 \$ 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 — Other current liabilities 338 320 Total current liabilities 53,922 46,729 Long-term debt and finance lease obligations, excluding current maturities (Note 7) 112,230 118,985 Professional liability insurance and other noncurrent (Note 3) 2,727 3,069 Estimated third-party payor settlements – noncurrent (Note 3) 2,727 3,069 Operating lease liability – noncurrent (Note 8) 12,365 — Deferred revenue and refundable advance fees 47,090 </td <td>Total current assets</td> <td></td> <td>233,245</td> <td></td> <td>213,771</td>	Total current assets		233,245		213,771		
Operating lease assets (Note 8) 13,983 — Noncurrent assets (Note 5) 13,583 3,428 Liabilities and net assets Current liabilities: Current maturities of long-term debt and finance lease obligations (Note 7) \$ 6,825 \$ 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 — Other current liabilities 338 320 Total current liabilities 53,922 46,729 Long-term debt and finance lease obligations, excluding current maturities (Note 7) 112,230 118,985 Professional liability insurance and other noncurrent liabilities (Note 9) 5,697 7,736 Estimated third-party payor settlements – noncurrent (Note 3) 2,727 3,069 Operating lease liability – noncurrent (Note 8) 12,365 — Deferred revenue and refundable advance fees 47,090 46,428 Total liabilities 234,031 222,947 Commitments and contingencies 230,19	Assets limited as to use – noncurrent (Note 4)		29,387		28,207		
Operating lease assets (Note 8) 13,983 — Noncurrent assets (Note 5) 13,583 3,428 Liabilities and net assets Current liabilities: Current maturities of long-term debt and finance lease obligations (Note 7) \$ 6,825 \$ 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 — Other current liabilities 338 320 Total current liabilities 53,922 46,729 Long-term debt and finance lease obligations, excluding current maturities (Note 7) 112,230 118,985 Professional liability insurance and other noncurrent liabilities (Note 9) 5,697 7,736 Estimated third-party payor settlements – noncurrent (Note 3) 2,727 3,069 Operating lease liability – noncurrent (Note 8) 12,365 — Deferred revenue and refundable advance fees 47,090 46,428 Total liabilities 234,031 222,947 Commitments and contingencies 230,19	Property, plant, and equipment, net (Note 6)		194,120		189,613		
Liabilities and net assets Current liabilities: Current maturities of long-term debt and finance lease obligations (Note 7) \$ 6,825 \$ 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 – Other current liabilities 338 320 Total current liabilities 338 320 Long-term debt and finance lease obligations, excluding current maturities (Note 7) 112,230 118,985 Professional liability insurance and other noncurrent (Note 8) 2,727 3,069 Professional liability insurance and other noncurrent (Note 3) 2,727 3,069 Operating lease liability – noncurrent (Note 8) 12,365 – Operating lease liability – noncurrent (Note 8) 12,365 – Deferred revenue and refundable advance fees 47,090 46,428 Total liabilities 234,031 222,947 Commitments and contingencies 230,192 195,743 Net assets without donor restrictions			13,983		_		
Liabilities and net assets Current liabilities: Current maturities of long-term debt and finance lease obligations (Note 7) \$ 6,825 \$ 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 – Other current liabilities 338 320 Total current liabilities 53,922 46,729 Long-term debt and finance lease obligations, excluding current maturities (Note 7) 112,230 118,985 Professional liability insurance and other noncurrent liabilities (Note 9) 5,697 7,736 Estimated third-party payor settlements – noncurrent (Note 3) 2,727 3,069 Operating lease liability – noncurrent (Note 8) 12,365 – Deferred revenue and refundable advance fees 47,090 46,428 Total liabilities 234,031 222,947 Commitments and contingencies 230,192 195,743 Net assets without donor restrictions 20,095 16,329	Noncurrent assets (Note 5)		13,583		3,428		
Current liabilities: Current maturities of long-term debt and finance lease obligations (Note 7) \$ 6,825 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 – Other current liabilities 338 320 Total current liabilities 53,922 46,729 Long-term debt and finance lease obligations, excluding current maturities (Note 7) 112,230 118,985 Professional liability insurance and other noncurrent liabilities (Note 9) 5,697 7,736 Estimated third-party payor settlements – noncurrent (Note 3) 2,727 3,069 Operating lease liability – noncurrent (Note 8) 12,365 – Deferred revenue and refundable advance fees 47,090 46,428 Total liabilities 234,031 222,947 Commitments and contingencies 230,192 195,743 Net assets without donor restrictions 20,095 16,329		\$	484,318	\$	435,019		
Current liabilities: Current maturities of long-term debt and finance lease obligations (Note 7) \$ 6,825 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 – Other current liabilities 338 320 Total current liabilities 53,922 46,729 Long-term debt and finance lease obligations, excluding current maturities (Note 7) 112,230 118,985 Professional liability insurance and other noncurrent liabilities (Note 9) 5,697 7,736 Estimated third-party payor settlements – noncurrent (Note 3) 2,727 3,069 Operating lease liability – noncurrent (Note 8) 12,365 – Deferred revenue and refundable advance fees 47,090 46,428 Total liabilities 234,031 222,947 Commitments and contingencies 230,192 195,743 Net assets without donor restrictions 20,095 16,329	Liabilities and net assets	-					
Current maturities of long-term debt and finance lease obligations (Note 7) \$ 6,825 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 – Other current liabilities 338 320 Total current liabilities 53,922 46,729 Long-term debt and finance lease obligations, excluding current maturities (Note 7) 112,230 118,985 Professional liability insurance and other noncurrent liabilities (Note 9) 5,697 7,736 Estimated third-party payor settlements – noncurrent (Note 3) 2,727 3,069 Operating lease liability – noncurrent (Note 8) 12,365 – Deferred revenue and refundable advance fees 47,090 46,428 Total liabilities 234,031 222,947 Commitments and contingencies Net assets Net assets without donor restrictions 230,192 195,743 Net assets with donor restrictions 20,095 16,329							
obligations (Note 7) \$ 6,825 \$ 6,635 Accounts payable and accrued expenses 41,906 38,487 Estimated third-party payor settlements – current (Note 3) 3,235 1,287 Operating lease liability – current (Note 8) 1,618 – Other current liabilities 338 320 Total current liabilities 53,922 46,729 Long-term debt and finance lease obligations, excluding current maturities (Note 7) 112,230 118,985 Professional liability insurance and other noncurrent liabilities (Note 9) 5,697 7,736 Estimated third-party payor settlements – noncurrent (Note 3) 2,727 3,069 Operating lease liability – noncurrent (Note 8) 12,365 – Deferred revenue and refundable advance fees 47,090 46,428 Total liabilities 234,031 222,947 Commitments and contingencies 230,192 195,743 Net assets with donor restrictions 20,095 16,329							
Accounts payable and accrued expenses Estimated third-party payor settlements – current (Note 3) Operating lease liability – current (Note 8) Other current liabilities Total current liabilities Total current debt and finance lease obligations, excluding current maturities (Note 7) Professional liability insurance and other noncurrent liabilities (Note 9) Estimated third-party payor settlements – noncurrent (Note 3) Operating lease liability – noncurrent (Note 8) Deferred revenue and refundable advance fees Total liabilities Net assets: Net assets: Net assets without donor restrictions Net assets with donor restrictions Net assets with donor restrictions Net assets with donor restrictions 112,965 112,365 1234,031 222,947 195,743 195,743 195,743 195,743		\$	6,825	\$	6,635		
Estimated third-party payor settlements – current (Note 3) Operating lease liability – current (Note 8) Other current liabilities Total current liabilities Total current liabilities Total current debt and finance lease obligations, excluding current maturities (Note 7) Professional liability insurance and other noncurrent liabilities (Note 9) Estimated third-party payor settlements – noncurrent (Note 3) Operating lease liability – noncurrent (Note 8) Deferred revenue and refundable advance fees Total liabilities Net assets: Net assets without donor restrictions Net assets with donor restrictions Net assets with donor restrictions Net assets with donor restrictions 1,287 1,618 - 1,619 - 1,619		•		•			
Operating lease liability – current (Note 8) Other current liabilities Total current liabilities Total current liabilities Total current liabilities Long-term debt and finance lease obligations, excluding current maturities (Note 7) Professional liability insurance and other noncurrent liabilities (Note 9) Sestimated third-party payor settlements – noncurrent (Note 3) Operating lease liability – noncurrent (Note 8) Deferred revenue and refundable advance fees Total liabilities Net assets: Net assets without donor restrictions Net assets with donor restrictions 16,329							
Other current liabilities 338 320 Total current liabilities 53,922 46,729 Long-term debt and finance lease obligations, excluding current maturities (Note 7) 112,230 118,985 Professional liability insurance and other noncurrent liabilities (Note 9) 5,697 7,736 Estimated third-party payor settlements – noncurrent (Note 3) 2,727 3,069 Operating lease liability – noncurrent (Note 8) 12,365 — Deferred revenue and refundable advance fees 47,090 46,428 Total liabilities 234,031 222,947 Commitments and contingencies Net assets: Net assets without donor restrictions 230,192 195,743 Net assets with donor restrictions 20,095 16,329					_		
Long-term debt and finance lease obligations, excluding current maturities (Note 7) Professional liability insurance and other noncurrent liabilities (Note 9) Estimated third-party payor settlements – noncurrent (Note 3) Operating lease liability – noncurrent (Note 8) Deferred revenue and refundable advance fees Total liabilities Total liabilities Net assets: Net assets without donor restrictions Net assets with donor restrictions Net assets with donor restrictions Net assets with donor restrictions 112,230 118,985 7,736 2,727 3,069 12,365 – 47,090 46,428 234,031 222,947					320		
current maturities (Note 7) Professional liability insurance and other noncurrent liabilities (Note 9) Estimated third-party payor settlements – noncurrent (Note 3) Operating lease liability – noncurrent (Note 8) Deferred revenue and refundable advance fees Total liabilities Total liabilities Net assets: Net assets without donor restrictions Net assets with donor restrictions Net assets with donor restrictions Net assets with donor restrictions 112,230 5,697 7,736 12,365 – 47,090 46,428 234,031 222,947 234,031 222,947	Total current liabilities		53,922		46,729		
current maturities (Note 7) Professional liability insurance and other noncurrent liabilities (Note 9) Estimated third-party payor settlements – noncurrent (Note 3) Operating lease liability – noncurrent (Note 8) Deferred revenue and refundable advance fees Total liabilities Total liabilities Net assets: Net assets without donor restrictions Net assets with donor restrictions Net assets with donor restrictions Net assets with donor restrictions 112,230 5,697 7,736 12,365 – 47,090 46,428 234,031 222,947 234,031 222,947	Long-term debt and finance lease obligations, excluding						
Professional liability insurance and other noncurrent liabilities (Note 9) Estimated third-party payor settlements – noncurrent (Note 3) Operating lease liability – noncurrent (Note 8) Deferred revenue and refundable advance fees Total liabilities Total liabilities Net assets: Net assets without donor restrictions Net assets with donor restrictions 15,697 7,736 2,727 3,069 12,365 - 47,090 46,428 234,031 222,947 230,192 195,743 Net assets with donor restrictions 230,192 195,743			112,230		118.985		
Estimated third-party payor settlements – noncurrent (Note 3) Operating lease liability – noncurrent (Note 8) Deferred revenue and refundable advance fees Total liabilities Commitments and contingencies Net assets: Net assets without donor restrictions Net assets with donor restrictions Net assets with donor restrictions Net assets with donor restrictions 230,192 195,743 Net assets with donor restrictions							
Operating lease liability – noncurrent (Note 8) Deferred revenue and refundable advance fees Total liabilities Commitments and contingencies Net assets: Net assets without donor restrictions Net assets with donor restrictions Net assets with donor restrictions 12,365 47,090 46,428 234,031 222,947 230,192 195,743 Net assets with donor restrictions 230,192 195,743	· · · · · · · · · · · · · · · · · · ·				,		
Deferred revenue and refundable advance fees Total liabilities Commitments and contingencies Net assets: Net assets without donor restrictions Net assets with donor restrictions Net assets with donor restrictions 230,192 195,743 16,329					_		
Total liabilities 234,031 222,947 Commitments and contingencies Net assets: Net assets without donor restrictions Net assets with donor restrictions 230,192 195,743 Net assets with donor restrictions 20,095 16,329					46,428		
Net assets:230,192195,743Net assets with donor restrictions20,09516,329	Total liabilities						
Net assets without donor restrictions230,192195,743Net assets with donor restrictions20,09516,329	Commitments and contingencies						
Net assets without donor restrictions230,192195,743Net assets with donor restrictions20,09516,329	Net assets:						
Net assets with donor restrictions 20,095 16,329			230,192		195,743		
1 of all net assets 250,28/ 212.0/2	Total net assets		250,287		212,072		
\$ 484,318 \$ 435,019		\$		\$			

Consolidated Statements of Operations

	Year Ended December 31 2019 2018					
		(In The	ousa			
Revenue:						
Net patient service revenue (Note 3)	\$	311,957	\$	293,367		
Other revenue (Note 13)		44,675		42,660		
Investment return (Note 4)		11,512		18,937		
Total revenue		368,144		354,964		
Expenses:						
Salaries and wages		138,902		135,054		
Employee benefits		37,320		38,204		
Professional fees		8,097		7,409		
Supplies and other expenses		140,214		134,710		
Depreciation and amortization		18,155		17,988		
Interest expense and amortization of financing costs		4,117		4,571		
Total expenses		346,805		337,936		
Income from operations		21,339		17,028		
Net change in unrealized gains and losses on investments (Note 4)		12,206		(16,905)		
Excess of revenue over expenses		33,545		123		
Net assets released from restrictions for capital purposes		904		1,170		
Change in net assets without donor restrictions	\$	34,449	\$	1,293		

Consolidated Statements of Changes in Net Assets

Years Ended December 31, 2019 and 2018

	Without Donor		1	With Donor		
	Restrictions		Restrictions		Total	
			(In	Thousands)		
Net assets at January 1, 2018	\$	194,450	\$	16,626	\$ 211,076	
Change in net assets without donor restrictions		1,293		_	1,293	
Contributions, investment return and other		_		1,676	1,676	
Net assets released from restrictions						
for operations		_		(803)	(803)	
Net assets released from restrictions						
for capital purposes		_		(1,170)	(1,170)	
Change in net assets		1,293		(297)	996	
Net assets at December 31, 2018		195,743		16,329	212,072	
Change in net assets without donor restrictions		34,449		_	34,449	
Contributions, investment return and other		_		5,518	5,518	
Net assets released from restrictions						
for operations		_		(848)	(848)	
Net assets released from restrictions						
for capital purposes		_		(904)	(904)	
Increase in net assets		34,449		3,766	38,215	
Net assets at December 31, 2019	\$	230,192	\$	20,095	\$ 250,287	

Consolidated Statements of Cash Flows

	Year Ended December 31 2019 2018				
		(In Tho	usan	eds)	
Operating activities	_				
Increase in net assets	\$	38,215	\$	996	
Adjustments to reconcile increase in net assets to net cash					
provided by operating activities:					
Depreciation and amortization		18,155		17,988	
Amortization of deferred financing costs and bond discount		74		288	
Cash received under nonrefundable advance fee plans, net of refunds		4,402		4,287	
Amortization of advance fees		(4,838)		(3,759)	
Net realized gains and losses on investments and income/loss					
in equity of joint ventures		(5,828)		(13,875)	
Net change in unrealized gains and losses on investments		(12,206)		16,905	
Changes in operating assets and liabilities:					
Patient accounts receivable, net		(2,516)		1,323	
Other assets		(17,887)		(2,403)	
Accounts payable and accrued expenses		3,419		1,224	
Professional liability insurance and other liabilities		(2,021)		(2,700)	
Estimated third-party payor settlements		1,606		(500)	
Net cash provided by operating activities		20,575		19,774	
Investing activities					
Acquisitions of property, plant, and equipment, net		(22,662)		(12,707)	
Short-term investments redeemed, net		1,408		2,142	
Assets limited as to use (purchased) redeemed, net		(1,253)		2,728	
Distributions from investment in joint ventures, net		2,184		2,381	
Net cash used in investing activities	-	(20,323)		(5,456)	
<u> </u>		(20,020)		(3,130)	
Financing activities		(C CO.T)		(10.010)	
Payments of long-term debt and finance lease obligations		(6,635)		(10,018)	
Cash received (disbursed) under refundable advance fee				(-)	
plans, net of refunds		1,098		(2,145)	
(Payment) refund of deferred financing costs		(4)		4	
Net cash used in financing activities		(5,541)		(12,159)	
Net (decrease) increase in cash and cash equivalents and restricted					
cash and restricted cash equivalents		(5,289)		2,159	
Cash and cash equivalents and restricted cash and restricted cash		· · · /		,	
equivalents at beginning of year		24,649		22,490	
Cash and cash equivalents and restricted cash and restricted cash)		,	
equivalents at end of year	\$	19,360	\$	24,649	
•	_				

Notes to Consolidated Financial Statements

December 31, 2019

1. Organization and Summary of Significant Accounting Policies

CentraState Healthcare System, Inc. (CSHS), located in Freehold, New Jersey, is a not-for-profit holding corporation.

A summary of significant accounting policies follows:

Principles of Consolidation

The consolidated financial statements include the accounts of CSHS, its wholly owned or wholly controlled subsidiary corporations and not-for-profit entities. CSHS is the sole member of the following not-for-profit corporations: CentraState Medical Center, Inc. (the Medical Center), CentraState Healthcare Affiliates, Inc. d/b/a The Manor (The Manor), CentraState Assisted Living, Inc. d/b/a Monmouth Crossing (Monmouth Crossing), CentraState Healthcare Foundation, Inc. (the Foundation), and Center for Aging, Inc. d/b/a Applewood (Applewood), wholly owned by The Manor. CSHS is the sole stockholder of CentraState Healthcare Services, Inc. (Healthcare Services), a for-profit corporation. Healthcare Services owns all of the membership interests of CentraState Medical Arts Building LLC (MAB), a limited liability company. CentraState Medical Associates, P.C. (Med Associates) and CentraState Specialists P.C., for-profit companies, are controlled subsidiaries of the Medical Center. In 2012, the System formed a captive insurance company domiciled in the Cayman Islands, CentraState Captive Insurance Company Ltd., SPC (the Cayman Captive), a wholly owned subsidiary of the Medical Center. The reporting entity resulting from the consolidation of these entities is referred to herein as the "System." All significant intercompany balances and transactions have been eliminated in consolidation. Although these entities have been consolidated for financial statement presentation, there may be limitations on the use of an entity's funds by another member of the group resulting from the charitable nature of some of the entities or other factors.

Summary information related to the entities follows:

The Medical Center is an acute care hospital whose mission is to provide the highest quality patient care for the central New Jersey community it serves. The Medical Center has 276 licensed beds. Applewood is a continuing care retirement community accredited by the Continuing Care Accreditation Committee. Applewood consists of 281 independent apartments, 20 cottages, 40 residential health care units, and a 60-bed skilled nursing facility. The Manor provides skilled nursing services for 123 elderly residential units including subacute, rehabilitation and I.V. therapy. Monmouth Crossing owns and operates an assisted

Notes to Consolidated Financial Statements (continued)

1. Organization and Summary of Significant Accounting Policies (continued)

living facility for the elderly consisting of 76 units with 59 units for memory care. The Foundation was established for the purpose of soliciting and investing funds for the benefit of the Medical Center and other not-for-profit entities of the System. Healthcare Services was established to provide various health care and related services to the community. MAB was organized to construct, develop, equip, and operate a medical arts building which offers state of the art ambulatory clinical programs. Med Associates was established for the purpose of aligning physician practices with the System. CentraState Specialists P.C. was formed for the purpose of providing specialized medical services to the community.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets, such as the valuation of accounts receivable for services to patients, and liabilities, such as estimated settlements with third-party payors and professional insurance liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements. Estimates also affect the amounts of revenue and expenses reported during the period. There is at least a reasonable possibility that certain estimates will change by material amounts in the near term. Actual results could differ from those estimates.

Cash and Cash Equivalents

The System considers all highly liquid investments with a maturity of three months or less at date of purchase to be cash and cash equivalents, except for amounts reported within short-term investments and assets limited as to use as such holdings are within investment portfolios, excluding assets held for indenture agreements. The System does not hold any money market funds with significant liquidity restrictions that would require the funds to be excluded from cash equivalents.

Notes to Consolidated Financial Statements (continued)

1. Organization and Summary of Significant Accounting Policies (continued)

A reconciliation of amounts reported on the consolidated balance sheets to the consolidated statements of cash flows as of and for the year ended December 31, 2019 and 2018 follows (in thousands):

	 2019	2018
Cash and cash equivalents	\$ 18,824	24,098
Assets limited as to use – by terms of indenture agreements: cash and cash equivalents	 536	551
Total cash and cash equivalents and restricted cash and restricted cash equivalents	\$ 19,360	24,649

Investments and Investment Return

Investments in marketable securities are reported in the consolidated balance sheets at fair value based on quoted market prices. Investments that are readily marketable and which are not reported as assets limited as to use are considered short-term investments and are classified as current assets in the accompanying consolidated balance sheets. All investments in marketable securities are classified as trading securities.

Investments in joint ventures, which have been entered into by Healthcare Services and the Medical Center, are accounted for using the equity method.

All investment transactions are recorded on the dates such trades take place. The realized gain or loss resulting from these transactions is the difference between the proceeds received and the average historical cost of the assets sold. Interest income is recorded as earned. Dividends are recorded on the ex-dividend date. Investment return and net change in unrealized gains and losses on investments is included in the excess of revenue over expenses unless restricted by donor or law.

Assets Limited as to Use

Assets limited as to use include investments internally designated by the Board of Trustees and various external designations. Donor restricted assets limited as to use include assets held under split-interest agreements, such as charitable gift annuity agreements, under which the Foundation pays the designated beneficiaries a predetermined annual annuity amount.

Notes to Consolidated Financial Statements (continued)

1. Organization and Summary of Significant Accounting Policies (continued)

Supplies

Supplies are reported in other current assets in the accompanying consolidated balance sheets and are stated at the lower of cost or net realizable value. Supplies are used in the provision of patient care and are not held for sale.

Pledges Receivable

Through the fundraising activities of the Foundation, the System is the recipient of pledges which are recorded at the time the unconditional promise to give is made, at estimated net realizable value. The net realizable value of the outstanding pledges of approximately \$1.6 million and \$662,000 at December 31, 2019 and 2018, respectively, are reported within other current assets in the accompanying consolidated balance sheets. The amount of the allowance for uncollectible pledges is based on management's assessment of historical and expected collections and other collection indicators. Additions to the allowance for uncollectible pledges result from the provision for uncollectible pledges. Pledges written off as uncollectible are deducted from the allowance for uncollectible pledges. Pledges are discounted to net present value based on the scheduled payment terms of each pledge using a discount rate of 2.17% for each of the years ended December 31, 2019 and 2018.

Property, Plant, and Equipment

Property, plant, and equipment are stated at cost, except for donated equipment which is recorded at fair value at the date of the gift. The System provides for depreciation on a straight-line basis over the estimated useful lives of such assets or the lease term, whichever is shorter. Amortization of equipment financed through finance lease obligations is included in depreciation and amortization expense.

Deferred Financing Costs

Deferred financing costs are amortized over the period the related obligation is outstanding using the effective interest method. Unamortized deferred financing costs are reported as direct deduction from long-term debt (see Note 7).

Notes to Consolidated Financial Statements (continued)

1. Organization and Summary of Significant Accounting Policies (continued)

Marketing Costs

Marketing and advertising costs incurred by the System, which are not subject to capitalization and deferral (none in 2019 or 2018), are expensed as incurred and amounted to approximately \$2.9 million and \$3.1 million for the years ended December 31, 2019 and 2018, respectively. Such costs are included in supplies and other expenses on the accompanying consolidated statements of operations.

Professional Liability Insurance

The System is insured for professional liability insurance through a wholly owned captive insurance company. Premiums paid by the System to the captive insurance company are determined annually based on claims-made coverage for health care professional liability and on an occurrence basis for general liability. Premiums are actuarially determined based on the actual and estimated experience of the System, subject to retrospective adjustment in future periods. Insurance premium revenue and expenses are eliminated in consolidation.

Retirement Community Obligations

Residents of Applewood are required to pay a fee to obtain a nontransferable right to lifetime occupancy at Applewood. Current residents have selected one of four continuing care contract options: Traditional Plan, 90% Refund Plan, 50% Refund Plan, or Fee for Service Plan. Applewood also offers a 100% Refund Plan.

The Traditional Plan specifies that advance fees are refundable to the resident on a declining balance basis amortized at 2% per month after residency is established. These advance fees are recorded as refundable advance fees upon receipt and amortized to income as performance obligations are satisfied using the straight-line method over the estimated remaining life expectancy of the resident, adjusted annually at the beginning of each year. The Fee for Service Plan requires residents to pay for health care related services on a fee for service basis.

Under the 90% and 50% Refund Plans, 10% and 50%, respectively, of the advance fees are nonrefundable. Nonrefundable fees are recorded as deferred revenue upon receipt and amortized to income as performance obligations are satisfied using the straight-line method over the estimated remaining life expectancy of the resident, adjusted annually.

Notes to Consolidated Financial Statements (continued)

1. Organization and Summary of Significant Accounting Policies (continued)

The refundable portion of these plans are refundable solely from the resale proceeds upon reoccupancy of the resident's unit, reduced by fees earned through the resident's use of Applewood's health center. The refundable portion of fees received is recorded as deferred revenue upon receipt.

Applewood annually calculates the present value (using a discount rate of 5% in 2019 and 2018) of the estimated net cost of future services and the use of facilities to be provided to current residents and compares that amount with the balance of deferred revenue from advance fees and refundable advance fees. No additional liability to provide future services and use of facilities was required to be recorded at December 31, 2019 and 2018.

Classification of Net Assets

The System separately accounts for and reports net assets with donor restrictions and net assets without donor restrictions. On a stand-alone financial reporting basis, the Medical Center, Applewood, Monmouth Crossing and The Manor recognize the balance and changes in their accumulated interest in the net assets of the Foundation. Amounts reported on a stand-alone basis are eliminated in consolidation.

Net assets without donor restrictions are not externally restricted for identified purposes by donors. Net assets without donor restrictions include resources that the governing board may use for any designated purpose and resources whose use is limited by agreement between the System and an outside party other than the donor. Net assets with donor restrictions are those whose use is limited by the donor. When a temporary donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, restricted net assets are reclassified to net assets without donor restrictions and reported as net assets released from restriction.

Net assets with donor restrictions that are perpetual in nature represent assets held in perpetuity by the Foundation on behalf of the Medical Center and Applewood, the proceeds of which are available to support the Medical Center and Applewood programs and services. The System follows the requirements of the New Jersey Uniform Prudent Management of Institutional Funds Act (NJ UPMIFA) as they relate to its permanently restricted contributions and net assets. The System's investment and spending policies for endowment assets attempt to provide a predictable stream of funding to the endowment funds.

Notes to Consolidated Financial Statements (continued)

1. Organization and Summary of Significant Accounting Policies (continued)

The System recognizes governmental grants where commensurate value is not exchanged as contributions when conditions and restrictions are satisfied and reports such amounts within other revenue (see Note 13).

Functional Expenses

The System provides general health care and other services. Expenses related to providing these services for the years ended December 31, 2019 and 2018 are as follows (in thousands):

	2019											
	Hospital tient Care		ost-Acute and ontinuing Care	P	nbulatory hysician ractices		Research		undations and ndraising		anagement and ministrative	Total
Salaries and wages Employee benefits Professional fees Supplies and other expenses Depreciation and amortization Interest	\$ 108,552 28,917 8,097 117,652 13,458 2,667	\$	18,391 5,745 - 15,030 3,928 716	\$	6,383 1,264 - 709 31 107	\$	220 55 - 89 -	\$	982 246 - 1,253 29	\$	4,374 1,093 - 5,481 709 627	\$ 138,902 37,320 8,097 140,214 18,155 4,117
Total	\$ 279,343	\$	43,810	\$	8,494	\$	364	\$	2,510	\$	12,284	\$ 346,805

	2018											
	Hospital tient Care		ost-Acute and ontinuing Care	P	nbulatory Physician Practices	1	Research		undations and ndraising		anagement and ministrative	Total
Salaries and wages	\$ 107,485	\$	17,604	\$	5,063	\$	324	\$	861	\$	3,717	\$ 135,054
Employee benefits	30,050		5,904		1,025		81		215		929	38,204
Professional fees	7,409		_		_		_		_		_	7,409
Supplies and other expenses	113,484		14,892		200		106		1,416		4,612	134,710
Depreciation and amortization	13,593		3,645		35		_		36		679	17,988
Interest	2,864		1,008		75		_		-		624	4,571
Total	\$ 274,885	\$	43,053	\$	6,398	\$	511	\$	2,528	\$	10,561	\$ 337,936

The accompanying consolidated financial statements report expense categories that are attributable to more than one health care service or support function. Costs not directly attributable to a function are allocated on a functional basis based on internal records and estimates.

Notes to Consolidated Financial Statements (continued)

1. Organization and Summary of Significant Accounting Policies (continued)

Performance Indicator

The accompanying consolidated statements of operations include excess of revenue over expenses as the performance indicator. Changes in net assets without donor restrictions which are excluded from the performance indicator include net assets released from restrictions for capital purposes.

Transactions deemed by management to be ongoing, major or central to the provision of health care services are reported within income from operations. Peripheral or incidental transactions are excluded from income from operations.

Income Taxes

The entities comprising the System, with the exception of Healthcare Services, MAB, Med Associates, CentraState Specialists P.C., and the Cayman Captive, are not-for-profit organizations as described in Section 501(c)(3) of the Internal Revenue Code (the Code) and are exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. The not-for-profit organizations are also exempt from state and local income taxes.

Healthcare Services, Med Associates, and CentraState Specialists P.C. are for-profit entities; however, income tax expense and income taxes paid for 2019 and 2018 were not significant. MAB is a single member limited liability company that is not recognized as a separate entity for tax purposes. For income tax purposes, the activities of MAB are treated as a division within its parent, Healthcare Services. The Cayman Captive is generally not subject to income taxes under the Cayman Islands tax concessions laws.

The System accounts for deferred tax assets and liabilities based on the differences between the financial reporting and tax basis of assets and liabilities using enacted tax rates and laws that will be in effect when differences are expected to reverse.

As of and for the years ended December 31, 2019 and 2018, the System has made reasonable estimates of the provision for income taxes and deferred tax balances based on accounting guidance included in Accounting Standards Codification 740, *Income Taxes*. The System will continue to refine its calculations in future periods as additional regulations and guidance are issued by the Internal Revenue Service (IRS).

Notes to Consolidated Financial Statements (continued)

1. Organization and Summary of Significant Accounting Policies (continued)

The Taxpayer Certainty and Disaster Tax Relief Act of 2019, signed into law on December 20, 2019 retroactively repealed Section 512(a)(7) of the Code which subjected amounts paid or incurred by an exempt organization to provide certain transportation fringe benefits to its employees to taxation as unrelated business taxable income. These amounts are not significant to the accompanying consolidated financial statements.

Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. (ASU) 2016-02, *Leases*, which requires the rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheets, including both finance leases (formally referred to as capital leases) and operating leases. ASU 2016-02 requires expanded disclosure related to lease agreements (See Note 8) to help the financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The recognition, measurement and presentation of expenses and cash flows arising from a lease primarily depend on its classification as a finance or operating lease.

The System adopted ASU 2016-02 effective January 1, 2019, following the modified retrospective method of application. As such, the 2018 consolidated financial statement amounts and disclosures have not been adjusted to reflect the provisions of the new standard. There was no cumulative-effect impact to the 2018 consolidated net assets as a result of the adoption. The System has made the transition-specific election to apply the package of practical expedients which allows for the carryforward of historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. Additionally, for operating leases entered into prior to January 1, 2019, the System has elected to utilize the operating leases' initial lease term to determine the discount rate used to initially measure the liability. Certain other accounting policy elections and quantitative and qualitative information pertaining to the System's adoption of ASU 2016-02 are described in Note 8.

Notes to Consolidated Financial Statements (continued)

1. Organization and Summary of Significant Accounting Policies (continued)

In November 2016, the FASB issued ASU 2016-18, *Statement of Cash Flows – Restricted Cash*, which requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The System adopted ASU 2016-18 in 2019 using a retrospective transition method.

In June 2018, the FASB issued ASU 2018-08, *Not-for-Profit Entities (Topic 958); Clarifying the Scope and Accounting Guidance for Contributions Received and Contributions Made.* ASU 2018-08 clarifies existing guidance in order to address diversity in practice in classifying grants (including governmental grants) and contracts received by not-for-profit entities, and requires entities to evaluate whether the resource provider receives commensurate value.

In addition, the standard clarifies the guidance on how entities determine when a contribution is conditional, including whether the agreement includes a barrier (or barriers) that must be overcome for the recipient to be entitled to the transferred assets and a right of return of the transferred assets (or a right of release of the promisor's obligation to transfer the assets). The standard was applied on a modified prospective basis to agreements that were not completed as of the effective date and to agreements entered into after the effective date. The System adopted ASU 2018-08 effective January 1, 2019. The adoption of ASU 2018-08 did not have a material impact on the System's consolidated financial statements.

Other Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The main objective of ASU 2016-13 and related ASU updates is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this Update are effective for the System for fiscal years beginning after December 15, 2022. The System is in the process of evaluating the impact of ASU 2016-13 on its consolidated financial statements.

Notes to Consolidated Financial Statements (continued)

1. Organization and Summary of Significant Accounting Policies (continued)

The FASB has amended certain guidance related to various disclosures in ASU 2018-13, *Technical Corrections and Improvements to Financial Instruments-Overall (Subtopic 825-10)-Recognition and Measurement of Financial Assets and Financial Liabilities.* ASU 2018-13 includes several disclosure changes involving transfers between the fair value levels and other updates related to fair value Level 3 investments. ASU 2018-13 also requires entities that use the practical expedient to measure the fair value of certain investments at their net asset values to disclose (1) the timing of liquidation of an investee's assets and (2) the date when redemption restrictions will lapse, but only if the investee has communicated this information to the entity or announced it publicly. The amendments in the Update are effective for the System for fiscal years beginning after December 15, 2019, with early adoption permitted. The System has not completed the process of evaluating the impact ASU 2018-13 on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other -Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. The standard aligns the requirement for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by this standard. The standard requires the customer in a hosting arrangement that is a service contract to follow the guidance in Accounting Standards Codifications Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense by determining which project stage an implementation activity relates to and the nature of the costs. The standard also requires the customer to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, among other provisions. The amendments in ASU 2018-15 are effective for annual reporting periods beginning after December 15, 2020, and interim periods thereafter. Early adoption is permitted. The amendments should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The System is in the process of evaluating the impact of ASU 2018-15 on its consolidated financial statements.

Reclassifications

Certain reclassifications have been made to 2018 financial statement disclosures to conform to the presentation in the 2019 consolidated financial statements.

Notes to Consolidated Financial Statements (continued)

2. Charity Care

The System provides care to patients who meet certain criteria defined by the New Jersey Department of Health (DOH) without charge or at amounts less than established rates. The Medical Center's records identify and monitor the level of charity care it provides and include the amount of charges foregone for services and supplies furnished. The current DOH charity care guidelines require participation and cooperation of the patient in order to be identified as a charity care account. Management believes that the present charity care guidelines understate the System's reported charity care amounts because of the difficulties involved with obtaining patient cooperation. The cost of charity care includes the direct and indirect cost of providing charity care services. The cost is estimated by utilizing a ratio of cost to standard charges applied to the standard uncompensated charges associated with providing charity care. The cost of charity care provided during the years ended December 31, 2019 and 2018 was approximately \$4.8 million and \$5.7 million, respectively. The System receives partial reimbursement for the charity care it provides (see Note 3).

3. Net Patient Service Revenue

Net patient service revenue is reported at the amount that reflects the consideration to which the System expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others and includes provisions for variable consideration (reductions to revenue) in determining a transaction price.

The System uses a portfolio approach as a practical expedient to account for categories of patient contracts as collective groups rather than recognizing revenue on an individual contract basis. The portfolios consists of major payor classes for inpatient revenue and major payer classes and types of services provided for outpatient revenue Based on historical collection trends and other analyses, the System believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

The System's initial estimate of the transaction price for services provided to patients subject to revenue recognition is determined by reducing the total standard charges related to the patient services provided by various elements of variable consideration, including contractual adjustments, discounts, implicit price concessions, and other reductions to the System's standard charges.

Notes to Consolidated Financial Statements (continued)

3. Net Patient Service Revenue (continued)

The System determines the transaction price associated with services provided to patients who have third-party payor coverage on the basis of contractual or formula-driven rates for the services rendered (see description of third-party payor payment programs below). The estimates for contractual allowances and discounts are based on contractual agreements, the System's discount policies and historical experience. For uninsured and under-insured patients who do not qualify for charity care, the System determines the transaction price associated with services rendered on the basis of charges reduced by implicit price concessions. Implicit price concessions included in the estimate of the transaction price are based on the System's historical collection experience for applicable patient portfolios.

Generally, the System bills patients and third-party payors several days after the services are performed and/or the patient is discharged. Net patient service revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the System. Net patient service revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total charges. The System believes that this method provides a reasonable depiction of the transfer of services over the term of the performance obligation based on the services needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients receiving inpatient acute care services or patients receiving services in the System's outpatient, ambulatory or long-term care centers. The System measures the performance obligation from admission into the System or the commencement of an outpatient service to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge or the completion of the outpatient visit.

Substantially all of its performance obligations relate to contracts with a duration of less than one year. The unsatisfied or partially unsatisfied performance obligations primarily relate to inpatient acute care services at the end of the reporting period for patients who remain admitted at that time (in-house patients). The performance obligations for in-house patients are generally completed when the patients are discharged, which for the majority of the System's in-house patients occurs within days or weeks after the end of the reporting period.

Subsequent changes to the estimate of the transaction price (determined on a portfolio basis when applicable) are generally recorded as adjustments to patient service revenue in the period of the change.

Notes to Consolidated Financial Statements (continued)

3. Net Patient Service Revenue (continued)

Changes in the System's estimates of implicit price concessions, discounts, contractual adjustments or other changes to expected payments for performance obligations satisfied in prior years were not significant. Portfolio collection estimates are updated based on collection trends. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay (determined on a portfolio basis when applicable) are recorded as bad debt expense. Bad debt expense for the years ended December 31, 2019 and 2018 was not significant.

The System has determined that the nature, amount, timing and uncertainty of revenue and cash flows are affected by the following factors: payors, lines of business and timing of when revenue is recognized. Tables providing details of these factors are presented below.

Net patient service revenue disaggregated by payor for the years ended December 31, 2019 and 2018 are as follows (in thousands):

	 2019	2018
Medicare	\$ 128,133	\$ 123,908
Medicaid	22,088	21,817
Commercial insurance	145,675	132,082
Self-pay patients	5,622	5,136
Other third-party payors	10,439	10,424
	\$ 311,957	\$ 293,367

Deductibles, copayments and coinsurance under third-party payment programs which are the patient's responsibility are included within the third-party payors amounts or self-pay category above.

Notes to Consolidated Financial Statements (continued)

3. Net Patient Service Revenue (continued)

Net patient service revenue for the years ended December 31, 2019 and 2018, disaggregated by lines of service is as follows (in thousands):

	 2019	2018
Hospital	\$ 293,627	\$ 274,247
Post-acute	13,333	14,850
Physician practices	 4,997	4,270
	\$ 311,957	\$ 293,367

At December 31, 2019 and 2018, patient accounts receivable, net is comprised of the following components (in thousands):

	 2019	 2018
Patient receivables Contract assets	\$ 27,368 1,497	\$ 24,718 1,631
0 0 11 11 10 11 11 11 11 11 11 11 11 11	\$ 28,865	\$ 26,349

Contract assets are related to in-house patients who were provided services during the reporting period but were not discharged as of the reporting date and for which the System may not have the right to bill.

Third-Party Payment Programs

The System has agreements with third-party payors that provide for payment for services rendered at amounts different from its established rates. A summary of the payment arrangements with major third-party payors follows:

Medicare: The System is paid for most Medicare inpatient and outpatient services under the national prospective payment system and other methodologies of the Medicare program for certain other services. Federal regulations provide for certain adjustments to current and prior years' payment rates, based on industry-wide and hospital-specific data. Medicare cost reports of the System have been audited and settled for years through 2015 at December 31, 2019, with the exception of 2011, which is still open.

Notes to Consolidated Financial Statements (continued)

3. Net Patient Service Revenue (continued)

Medicaid: Inpatient acute care services rendered to Medicaid program beneficiaries are paid at prospectively determined rates per discharge. Outpatient services rendered to Medicaid program beneficiaries are reimbursed under cost-based and fee schedule methodologies. The System is reimbursed for outpatient services at a tentative rate, with final settlement determined after submission of annual cost reports and audits thereof by the Medicaid fiscal intermediary. The Medicaid cost reports of the System for years through 2016 have been audited and settled.

Other third-party payors: The System also has entered into payment agreements with certain commercial insurance carriers and health maintenance organizations. The basis for payment to the System under these agreements includes prospectively determined rates per discharge or days of hospitalization and discounts from established charges.

Medicare and Medicaid cost reports, which serve as the basis for final settlement with these programs, have been audited by the applicable fiscal intermediary and settled through years noted above, although revisions to final settlements or other retroactive changes could be made. Other years and various issues remain open for audit and settlements.

Settlements with third-party payors for cost report filings and retroactive adjustments due to ongoing and future audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the System's historical settlement activity (for example, cost report final settlements or repayments related to recovery audits), including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Such estimates are determined through either a probability-weighted estimate or an estimate of the most likely amount, depending on the circumstances related to a given estimated settlement item. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. For the years ended December 31, 2019 and 2018, the net effect of the System's revisions to prior year Medicare and Medicaid settlement estimates, as well as settlements with commercial insurers, resulted in net patient service increasing by approximately \$11.3 million and \$5.4 million, respectively. These amounts were portions of commercial non-recurring settlements totaling \$20.0 million and \$12.0 million in 2019 and 2018, respectively, which were one-time increases to 2019 and 2018 net patient service revenue.

Notes to Consolidated Financial Statements (continued)

3. Net Patient Service Revenue (continued)

The System has appealed certain items in audited cost reports. The outcome of these appeals is uncertain and, therefore, potential revenue associated with these appeals is not included within the accompanying consolidated statements of operations.

There are various proposals at the federal and state levels that could, among other things, significantly reduce payment rates or modify payment methods. The ultimate outcome of these proposals and other market changes, including the potential effects of or changes to health care reform that has been or will be enacted by the federal government, cannot presently be determined. Future changes in the Medicare and Medicaid programs and any reduction of funding could have an adverse impact on the System.

Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. The System believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing that could have a material adverse effect on its financial statements. Noncompliance with such laws and regulations could result in fines, penalties and exclusion from such programs.

The New Jersey Health Care Subsidy Fund and other state programs have been established for various purposes including the distribution of charity care payments to hospitals statewide. The following subsidy amounts have been included in net patient service revenue (in thousands):

	Year Ended December 31							
		2019	2018					
Charity care	\$	517 9	388					
Special subsidy	*	419	419					
Medicaid GME		309	303					
Delivery System Reform Incentive Payments		234	401					
	\$	1,479	3 1,511					

Notes to Consolidated Financial Statements (continued)

4. Investments and Assets Limited as to Use

Short-Term Investments

Short-term investments consist of the following (in thousands):

	December 31			
		2019		2018
United States government obligations	\$	23,402	\$	25,091
Corporate bonds		17,071		17,213
Common stocks		5,763		5,467
Mutual funds		118,405		102,649
		164,641		150,420
Interest receivable		282		205
	\$	164,923	\$	150,625

Assets Limited as to Use

Assets limited as to use consist of the following (in thousands):

	December 31			
	2019		2018	
Cash and cash equivalents	\$	11,667 \$	11,157	
Common stocks		1,626	1,674	
United States government obligations		3,334	3,815	
Corporate bonds		2,050	3,770	
Mutual funds		11,804	8,827	
Total assets limited as to use		30,481	29,243	
Less current portion		1,094	1,036	
Assets limited as to use – noncurrent	\$	29,387 \$	28,207	

Notes to Consolidated Financial Statements (continued)

4. Investments and Assets Limited as to Use (continued)

Assets limited as to use are maintained for the following purposes (in thousands):

	December 31			
		2019	2018	
As directed by the Board of Trustees	\$	4,856 \$	4,856	
By terms of indenture agreements		536	551	
Estimated advance fee refunds		3,118	2,916	
Supplemental executive retirement plan		1,434	1,221	
By donor restrictions		14,508	12,326	
Assets held in the Cayman Captive (Note 9)		6,029	7,373	
	\$	30,481 \$	29,243	

A summary of assets limited as to use by terms of indenture agreement is as follows (in thousands):

	December 31				
		2019			
Debt service interest funds Debt service cost of issuance funds	\$	536	\$	547 4	
	\$	536	\$	551	

Notes to Consolidated Financial Statements (continued)

4. Investments and Assets Limited as to Use (continued)

Investment Return

Investment return without donor restrictions consists of the following (in thousands):

	Year Ended December 31			
	2019		2018	
Revenue from operations:	·			
Interest and dividends	\$	5,684	\$ 5,062	
Net realized gains and losses		3,500	11,611	
Net gain in equity of joint venture investments		2,328	2,264	
		11,512	18,937	
Nonoperating income (loss):				
Net change in unrealized gains and losses on				
investments		12,206	(16,905)	
Total investment return – without donor restrictions	\$	23,718	\$ 2,032	

5. Noncurrent Assets

Noncurrent assets consist of the following (in thousands):

	December 31			
		2019		2018
Investments in joint ventures	\$	1,932	\$	1,789
Investment in Vermont RRG (Note 9) Other noncurrent assets		- 11,651		15 1,624
	\$	13,583	\$	3,428

Included in investments in joint ventures under which Healthcare Services holds 50% ownership interests are the following companies: CentraState Fitness & Wellness Center LLC (F&W), Freehold Venture Associates, LP, and CentraState Healthcare Network. F&W leases space from the Medical Center. The remaining term of the lease with the Medical Center is 9 years, with the option to renew for three terms of 10 years each (annual rental payments of approximately \$500,000 per year). Distributions received from these joint ventures for 2019 and 2018 totaled approximately \$2.2 million and \$2.4 million, respectively.

Notes to Consolidated Financial Statements (continued)

6. Property, Plant, and Equipment

Property, plant, and equipment consist of the following (in thousands):

	December 31			
	2019			2018
Land	\$	16,712	\$	16,712
Land improvements		11,005		8,279
Buildings and fixtures		307,952		304,442
Equipment		191,820		175,576
		527,489		505,009
Less accumulated depreciation and amortization		336,204		318,056
Add construction in progress		2,835		2,660
	\$	194,120	\$	189,613

Equipment and facilities acquired through finance lease obligations are included in the amounts above, including approximately \$25,000 and \$75,000 of unamortized balances at December 31, 2019 and 2018, respectively. During 2019 and 2018, approximately \$50,000 was amortized for these equipment and facilities costs.

Notes to Consolidated Financial Statements (continued)

7. Long-Term Debt and Finance Lease Obligations

Long-term debt and finance lease obligations consist of the following (in thousands):

	December 31			· 31
		2019		2018
Series 2010 CAP Loan – Medical Center (a)	\$	917	\$	1,917
Series 2012 Note – Medical Center (b)		25,038		25,263
Series 2014 Bonds – Medical Center (c)		33,350		36,430
Series 2017A Bonds – Medical Center (d)		32,670		33,225
Series 2005B Bonds – Applewood (e)		21,860		22,865
Series 2000 Bonds – MAB (f)		5,635		6,355
Finance lease obligation at a rate of 4.25%, collateralized				
by leased equipment and facilities maturing in 2021		43		93
		119,513		126,148
Less:				
Unamortized bond discount		3		7
Deferred financing costs, net		455		521
Current maturities		6,825		6,635
Long-term debt and finance lease obligations,				
excluding current maturities	\$	112,230	\$	118,985

(a) CentraState Medical Center – On November 30, 2010, the New Jersey Health Care Facilities Financing Authority (NJHCFFA) approved a \$10.0 million loan through the Hospital Capital Asset Financing Program (Series 2010 CAP Loan). The loan proceeds were used by the Medical Center for the relocation and expansion of the radiation oncology department, purchase of certain equipment, and costs associated with the financing. Principal payments were payable in monthly amounts sufficient to amortize the principal balance over a ten-year period through the maturity date of December 1, 2017, at which time all unpaid balance was due. On November 22, 2017, the NJHCFFA extended the term of the loan to December 1, 2020, at which point the unpaid principal balance and interest are due. The Series 2010 CAP Loan bears variable interest, which was 2.29% and 4.38% at December 31, 2019 and 2018, respectively. The Series 2010 CAP Loan is collateralized by the gross receipts of the Medical Center and a mortgage lien on certain of the Medical Center's real property.

Notes to Consolidated Financial Statements (continued)

7. Long-Term Debt and Finance Lease Obligations (continued)

- (b) CentraState Medical Center On April 26, 2012, the Medical Center executed a loan agreement for an approximately \$26.5 million promissory note with a bank (the Series 2012 Note). Principal payments are due annually through July 1, 2037. The Series 2012 Note bears interest at a variable rate established monthly (2.9% and 3.50% at December 31, 2019 and 2018, respectively). The interest rate can be converted to a fixed rate, at the option of the Medical Center, pursuant to the loan agreement.
- (c) CentraState Medical Center In 1998, the NJHCFFA issued Series 1998 Bonds on behalf of the Medical Center. On August 14, 2014, the System fully refunded the outstanding Series 1998 Bond with proceeds from the issuance of Series 2014 Bonds issued by the NJHCFFA on behalf of the Medical Center.
 - The NJHCFFA issued approximately \$48.1 million of Series 2014 Bonds. In addition to the refunding of the Series 1998 Bonds, the proceeds were used to construct a new information technology building and fund certain Medical Center renovations. At December 31, 2019, the bonds consist of approximately \$26.3 million of Series 2014A Bonds with an interest rate of 2.9%, maturing annually through July 1, 2028; approximately \$7.0 million of Series 2014C bonds with an interest rate of 3%, maturing annually through July 1, 2029. The 2014 Bonds are collateralized by the gross receipts of the Medical Center and a first mortgage lien on certain of the Medical Center's real property.
- (d) CentraState Medical Center In December 2017, the NJHCFFA issued approximately \$33.5 million of Series 2017A Bonds on behalf of the Medical Center. A portion of the proceeds, together with the remaining debt service reserve funds, were used to defease previously outstanding Series 2006A Bonds. On December 21, 2017, the System funded an escrow account, held by a trustee, to pay the Series 2006A Bonds bondholders at a future redemption date. On January 8, 2018, a final redemption occurred in the amount of approximately \$38.3 million.

The Series 2017A Bonds mature annually through July 1, 2037, with an interest rate of 3.26%. The Series 2017A Bonds are collateralized by a pledge of gross receipts and a first mortgage lien on the Medical Center's real property.

Notes to Consolidated Financial Statements (continued)

7. Long-Term Debt and Finance Lease Obligations (continued)

(e) Applewood – Series 2005A, 2005B and 2005C Bonds (collectively, the 2005 Bonds) were issued by the New Jersey Economic Development Authority (NJEDA) on behalf of Applewood to fund the construction and expansion of the Applewood project and for the repayment of previously outstanding NJEDA Variable Rate Revenue Bonds, Applewood Center for Aging, Inc., Series 1989. The Series 2005A and 2005C Bonds have been fully repaid in prior years.

The Series 2005B Bonds were scheduled to mature through 2035 and bear interest at variable rates determined weekly based on remarketing activities and not to exceed 10% (1.23% and 1.59% at December 31, 2019 and 2018, respectively).

The holders of the Series 2005B Bonds have the right to tender their bonds for purchase on a weekly basis. Applewood has irrevocable letters of credit with a bank which provide security for the payment of the principal and interest on the Series 2005B Bonds. The letter of credit is collateralized by a security interest in the mortgage of Applewood's property, plant, and equipment and a security interest in the gross revenues and advance fees of Applewood.

In February 2020, Applewood refinanced the Series 2005B Bonds through a private placement debt offering with National Finance Authority and a bank, maturing in October 2035 with interest at a fixed rate of 2.38%.

(f) CentraState Medical Arts Building - On December 28, 2000, MAB issued Series 2000 Bonds to finance the construction and equipping of the medical arts building. The Series 2000 Bonds mature December 1, 2025, with interest at a variable rate based on remarketing activities (not to exceed 15%, while the bonds bear interest at a weekly rate or 25% if the bonds are converted to a term rate) which was 1.89% and 2.04% at December 31, 2019 and 2018, respectively. The holders of the Series 2000 Bonds have the right to tender their bonds for purchase on a weekly basis. MAB has an irrevocable letter of credit with a bank, providing security for the payment of principal and interest on the Series 2000 Bonds. The letter of credit is collateralized by a first priority lien and security interests in substantially all of MAB's real property, assets, and leases (the Medical Center leases the medical arts building and the lease payment amounts are based on MAB's debt service under the Series 2000 Bonds). The reimbursement terms of the letter of credit are such that in the event that a bondholder demanded repayment on the bonds and adequate funds are not available from the remarketing of such bonds, the letter of credit would be drawn and MAB would reimburse the bank which issued the letter of credit over a long-term period. The letter of credit has been extended through several amendments and currently expires September 1, 2021.

Notes to Consolidated Financial Statements (continued)

7. Long-Term Debt and Finance Lease Obligations (continued)

The reimbursement terms of the letter of credit also provide that the existing letter of credit will be drawn if a replacement letter of credit has not been executed prior to expiration and is to be paid over a long-term period. The available amount of the letter of credit at December 31, 2019 is approximately \$5.8 million.

Debt issued by each entity of the System is the sole responsibility of that entity.

Principal payments on long-term debt and finance lease obligations for the next five years and thereafter are as follows (in thousands):

	ng-Term	bligations ler Finance	
	 Debt	Leases	Total
2020	\$ 6,782	\$ 43	\$ 6,825
2021	6,070	_	6,070
2022	6,365	_	6,365
2023	6,690	_	6,690
2024	6,960	_	6,960
Thereafter	 86,603	_	86,603
	\$ 119,470	\$ 43	\$ 119,513

At December 31, 2019 and 2018, the entities comprising the System were in compliance with the financial covenants of their respective loan agreements.

Interest paid under all borrowings for years ended December 31, 2019 and 2018 aggregated approximately \$4.1 and \$4.6 million, respectively, net of capitalized interest.

Notes to Consolidated Financial Statements (continued)

8. Leases

As described in Note 1, the System adopted ASU 2016-02 effective January 1, 2019. The System leases certain property and equipment under finance and operating leases. Leases are classified as either finance or operating leases based on the underlying terms of the agreement and certain criteria, such as the term of the lease relative to the useful life of the asset and the total lease payments to be made as compared to the fair value of the asset, amongst other criteria. Finance leases result in an accounting treatment similar to an acquisition of the asset.

For leases with initial terms greater than a year (or initially greater than one year remaining under the lease at the date of adoption of ASU 2016-02), the System records the related right-of-use assets and liabilities at the present value of the lease payments to be paid over the life of the related lease. The System's leases may include variable lease payments and renewal options. Variable lease payments are excluded from the amounts used to determine the right-of-use assets and liabilities unless the variable lease payments depend on an index or rate or are in substance fixed payments. Lease payments related to periods subject to renewal options are also excluded from the amounts used to determine the right-of-use assets and liabilities unless the System is reasonably certain to exercise the option to extend the lease. The present value of lease payments is calculated by utilizing the discount rate stated in the lease, when readily determinable. For leases for which this rate is not readily available, the System has elected to use a risk-free discount rate determined using a period comparable with that of the lease term. The System has made an accounting policy election to separate lease components from nonlease components in contracts when determining its lease payments for its asset classes except for medical equipment, as permitted by ASU 2016-02. As such, the System does not account for the applicable nonlease components together with the related lease components when determining the right-of-use assets and liabilities.

The System has made an accounting policy election not to record leases with an initial term of less than a year as right-of-use assets and liabilities.

Notes to Consolidated Financial Statements (continued)

8. Leases (continued)

The following schedule summarizes information related to the lease assets and liabilities as of and for the year ended December 31, 2019 (in thousands):

Lease cost: Finance lease cost: Amortization of right-of-use asset Interest on lease liabilities Operating lease cost	\$	50 3 2,195
Total lease cost	\$	2,248
Right-of-use assets and liabilities: Right-of-use assets – finance leases Lease liability – finance leases Right-of-use assets – operating leases Lease liability – operating leases	\$	25 43 13,983 13,983
Other information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases Operating cash flows from operating leases Financing cash flows from finance leases	\$	3 2,195 50
Right-of-use assets obtained in exchange for new finance lease liabilities Right-of-use assets obtained in exchange for new operating lease liabilities		-
Weighted-average remaining lease term – finance leases Weighted-average remaining lease term – operating leases Weighted-average discount rate – finance leases Weighted-average discount rate – operating leases	1	10 months 9 years 4.25% 4.5%

Notes to Consolidated Financial Statements (continued)

8. Leases (continued)

For finance leases, right-of-use assets are recorded in property, plant and equipment and lease liabilities are recorded in long-term debt and finance lease obligations in the accompanying consolidated balance sheets. For operating leases, right-of-use assets are recorded in operating lease assets, and lease liabilities are recorded in operating lease liability, current and noncurrent, in the accompanying consolidated balance sheets.

The following table reconciles the undiscounted lease payments to the lease liabilities recorded on the accompanying consolidated statement of financial position at December 31, 2019 (in thousands):

	Fina	Finance leases		erating leases
	·		•	
2020	\$	43	\$	2,213
2021		_		2,079
2022		_		1,862
2023		_		1,791
2024		_		1,604
Thereafter		_		7,927
Total lease payments		43		17,476
Less imputed interest		_		3,493
Total lease obligation		43		13,983
Less current portion		43		1,618
Long-term portion	\$	_	\$	12,365

9. Professional Liability Insurance

Through April 30, 2003, the System maintained claims-made professional liability coverage through a commercial insurance carrier.

Effective May 1, 2003, the System, in conjunction with other health care entities, participated in the formation of a captive insurance company, System and Affiliate Members, Limited, a Bermuda domiciled organization (the Bermuda Captive), to provide professional liability and general liability insurance to its participants at a primary level.

Notes to Consolidated Financial Statements (continued)

9. Professional Liability Insurance (continued)

Effective January 1, 2013, the System withdrew from the Bermuda Captive and as of this date primary professional and general liability insurance coverage is provided by the Cayman Captive, including assumption of the period of claims that were previously covered by the Bermuda Captive. As discussed in Note 1, the Cayman Captive is a wholly owned subsidiary of the Medical Center. The Cayman Captive is reflected in the System's consolidated financial statements within the Medical Center as follows:

		December	· 31
		2019	2018
Included in assets limited as to use: Cash and investments	\$	6,029 \$	7,373
Included within professional liability insurance:		2.250	5 .026
Other assets		3,259	5,026
Professional liabilities		(5,802)	(9,932)
Equity in Cayman Captive	<u>\$</u>	3,486 \$	2,467

In February 2007, the System invested in a captive insurance company domiciled in Vermont (Vermont RRG) to provide voluntary attending physicians insurance coverage. Premiums for the Vermont RRG are paid by the participating physicians; however, the participating hospitals are responsible for funding a portion of the Vermont RRG's capital and surplus requirements.

During 2014, the obligations of the Vermont RRG for the periods 2007 through 2012 were transferred to the Cayman Captive through a novation. During 2017, the obligations and assets of the Vermont RRG, for all activity subsequent to December 31, 2012, were also transferred to the Cayman Captive through a novation. The System's investment in the Vermont RRG at December 31, 2017 was approximately \$400,000 following the novation. The System's investment in the Vermont RRG at December 31, 2018 approximated \$15,000 (\$0 at December 31, 2019).

Under the professional and general liability programs, as it pertains to the System, a self-insured retention exists for primary coverage. Through April 30, 2004, the self-insured retention covered individual claims up to \$250,000 or total claims aggregating \$750,000. Beginning May 1, 2004, the self-insured retention was increased to \$500,000 for individual claims or total claims aggregating \$1.5 million. Effective May 1, 2006, the self-insured retention was increased to \$1.0 million for individual claims or total claims aggregating \$3.0 million in the policy year and has remained at the level since then.

Notes to Consolidated Financial Statements (continued)

9. Professional Liability Insurance (continued)

After the self-insured retention, the System carries a \$20.0 million buffer policy and a \$10.0 million excess umbrella liability policy with two separate commercial insurance carriers. As required by Vermont law, the System also carried a \$1.0 million excess policy, above the aforementioned \$20 million, with the Vermont RRG.

In addition, the System recorded actuarially determined liabilities related to claims incurred but not reported and amounts insured above the primary insurance coverage layer of approximately \$900,000 at December 31, 2019 and 2018. The professional liabilities are undiscounted and are included in professional liability insurance and other noncurrent liabilities at approximately \$3.7 million and \$6.1 million at December 31, 2019 and 2018, respectively.

As of January 1, 2012, the System is self-insured for workers' compensation claims through a large deductible, paid loss retro program with a commercial carrier. Prior to January 1, 2012, workers' compensation claims were commercially insured on a fixed cost basis.

Professional liability insurance and other noncurrent liabilities consist of the following:

December 31											
	2019	2018									
\$	3,259 \$	5,026									
	(5,802)	(9,932)									
	(557)	(429)									
	(2,597)	(2,401)									
\$	5,697 \$	(7,736)									
	\$ \$	\$ 3,259 \$ (5,802) (557) (2,597)									

The System's estimates for professional liabilities are based upon complex actuarial calculations which utilize factors such as historical claims experience for the System and related industry factors, trending models, and estimates for the payment patterns of future claims. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. The estimated professional liabilities recorded at December 31, 2019 and 2018 are subject to revision as actual experience or other factors impacting the estimates become known or are anticipated.

Notes to Consolidated Financial Statements (continued)

10. Pension Plans

The System sponsors a defined contribution pension plan (the 401(a) Plan) covering all eligible employees. Employees are eligible to participate in the 401(a) Plan following the completion of one year of service, as defined in the 401(a) Plan document, and the attainment of age 21. The System contributes a percentage of eligible salaries on an annual basis (5% for 2019 and 2018), net of forfeitures. Eligible salaries exclude certain items such as overtime. Additionally, the System sponsors another defined contribution plan (the 403(b) Plan) which prior to 2004 included only employee contributions. Beginning in 2004, the System contributes amounts to the 403(b) Plan based on a match of employee contributions. Pension expense under both pension plans aggregated approximately \$7.0 million and \$6.8 million for the years ended December 31, 2019 and 2018, respectively.

The System also sponsors a defined contribution supplemental executive retirement plan (SERP) for certain employees and a 457(b) eligible deferred compensation plan available to all executives. Total pension expense under the SERP plan was approximately \$185,000 and \$74,000 for the years ended December 31, 2019 and 2018, respectively.

11. Concentrations of Credit Risk

At December 31, 2019 and 2018, the System has its cash, including amounts classified within short-term investments, assets limited as to use and other noncurrent assets, deposited in several financial institutions. Investments in money market funds are not guaranteed by the U.S. government. Cash held in certain interest-bearing accounts is not fully insured. Exposure to any individual financial institution does not exceed 62% of the System's total cash balance. Management considers the credit risk related to these deposits to be minimal.

The System's health care providing entities grant credit without collateral to their patients, most of whom are local residents and are insured under third-party payor agreements. Concentrations of gross accounts receivable from patients and third-party payors were as follows:

	Decem	ber 31
	2019	2018
Medicare	47%	47%
Medicaid	7	7
Managed care – insurance companies	29	29
Other third-party payors	10	10
Patients	7	7
	100%	100%

Notes to Consolidated Financial Statements (continued)

12. Commitments and Contingencies

Various lawsuits and claims arising in the normal course of operations are pending or are on appeal against the System. Such lawsuits and claims are either specifically covered by insurance, included in estimated liabilities for self-insured exposure levels, or are not material. While the outcome of these lawsuits cannot be determined at this time, management believes that any loss which may arise from the System's actions will not have a material adverse effect on the System's consolidated financial position or results of operations.

Applewood is regulated by the New Jersey Department of Community Affairs pursuant to the Continuing Care Retirement Community Regulation and Financial Disclosure Act (the Act). The Act requires, among other things, that Applewood establish and maintain liquid reserves which generally are equal to the greater of 15% of the projected annual operating expenses (excluding depreciation) or the principal and interest due on the bonds in the next 12 months. Applewood has complied with that requirement at December 31, 2019 and 2018.

13. Other Revenue

Other revenue consists of the following (in thousands):

	Ye	ear Ended	Dec	ember 31
		2019		2018
Residential services revenue, including amortization income of approximately \$4.8 million and \$3.8 million				
in 2019 and 2018, respectively	\$	28,476	\$	27,432
Rental income		4,535		4,614
Grants and community health programs		453		499
Net assets released from restrictions for operations		848		803
Food services		1,646		1,612
Vendor rebates		1,044		858
Other		7,673		6,842
	\$	44,675	\$	42,660

Notes to Consolidated Financial Statements (continued)

13. Other Revenue (continued)

Residential services revenue is reported within other revenue at amounts that reflect the consideration the System expects to receive in exchange for the services provided. These amounts are due from residents or third-party payors and include provisions for variable consideration. Performance obligations are determined based on the nature of the services provided. Resident services revenue including amortization of advance fees are recognized as performance obligations are satisfied.

14. Fair Value Measurements

For assets and liabilities required to be measured at fair value, the System measures fair value based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are applied based on the unit of account from the System's perspective. The unit of account determines what is being measured by reference to the level at which the asset or liability is aggregated (or disaggregated) for purposes of applying other accounting pronouncements.

The System follows a valuation hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

- Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
- Level 2: Observable inputs that are based on inputs not quoted in active markets, but corroborated by market data.
- Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In determining fair value, the System uses valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers nonperformance risk in its assessment of fair value.

Notes to Consolidated Financial Statements (continued)

14. Fair Value Measurements (continued)

Financial assets and liabilities carried at fair value as of December 31, 2019 and 2018, are classified in the table below in one of the three categories described above (in thousands):

				201	9	
		Level 1		Level 2	Level 3	Total
Assets:						
Cash and cash equivalents – held						
for investments	\$	11,667	\$	- \$	S - S	11,667
United States government						
obligations		26,736		_	_	26,736
Corporate bonds		16,786		2,335	_	19,121
Common stocks – large cap		7,389		_	_	7,389
Mutual funds:						
Fixed income		80,004		_	_	80,004
Equities – small cap		3,838		_	_	3,838
Equities – large cap		29,436		_	_	29,436
International equity	_	16,931	_			16,931
	\$	192,787	\$	2,335	\$ - \$	195,122
				201	0	
		Level 1		Level 2	Level 3	Total
Assets:		Level 1		Level 2	Level 3	Total
Cash and cash equivalents – held						
for investments	\$	11,157	2	_ 5	\$ - \$	11,157
United States government	Ψ	11,137	Ψ		φ — φ	11,137
obligations		28,906		_	_	28,906
Corporate bonds		16,926		4,057	_	20,983
Common stocks – large cap		7,102		39	_	7,141
Mutual funds:		7,102		37		7,111
Fixed income		55,472		_	_	55,472
Equities – small cap		986		_	_	986
Equities – large cap						
Equities – large cap		51,531		_	_	51,531
International equity		51,531 2,966		521	_	51,531 3,487

Notes to Consolidated Financial Statements (continued)

14. Fair Value Measurements (continued)

Fair value for Level 1 is based upon quoted prices in active markets. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. While the System believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. A financial instrument's categorization within the three levels of the valuation hierarchy is not indicative of the investment risk associated with the underlying assets.

The carrying values of cash, patient receivables, accounts payable and accrued expenses, other current assets and liabilities are reasonable estimates for fair value due to the short-term nature of these financial instruments.

15. Liquidity and Available Resources

The table below represents financial assets available for general expenditures within one year at December 31, 2019 and 2018 (in thousands):

	2019	2018
Financial assets at year-end:	1	
Cash and cash equivalents	\$ 18,824	\$ 24,098
Short-term investments	164,923	150,625
Assets limited as to use	30,481	29,243
Receivables for patient care, net	28,865	26,349
Current portion of pledges receivable, net	1,624	662
Total financial assets	244,717	230,977
Less amounts not available to be used within one year: Assets limited as to use	29,387	28,207
Financial assets available to meet general expenditures over the next twelve months	\$ 215,330	\$ 202,770

Notes to Consolidated Financial Statements (continued)

15. Liquidity and Available Resources (continued)

The System has other assets limited as to use for donor-restricted purposes, debt service, refundable advance fees, supplemental retirement plan and professional liabilities. These assets limited as to use, which are more fully described in Note 4 are not available for general expenditure within the next year and are not reflected in the amounts above.

As part of the System's liquidity management plan, cash in excess of daily requirements are invested in short-term investments and money market funds. Occasionally, the Board designates a portion of any operating surplus to an operating reserve, which was \$4.9 million as of December 31, 2019 and 2018. This fund established by the Board of Trustees may be drawn upon, if necessary, to meet unexpected liquidity needs.

As of December 31, 2019 and 2018, the System was in compliance with financial covenants; see Note 7.

16. Events Subsequent to December 31, 2019

Subsequent events have been evaluated through April 15, 2020 which is the date the accompanying consolidated financial statements were issued. Except as disclosed in Note 7 and below, no subsequent events have occurred that require disclosure in or adjustments to the accompanying consolidated financial statements.


Subsequent to December 31, 2019, the System announced a clinical affiliation with Atlantic Health System (Atlantic Health) that will provide enhanced access to high-quality specialty health care services to the communities of central New Jersey. The affiliation will accelerate the growth of the System's oncology and neuroscience programs through linkages with Atlantic Health's nationally recognized specialists and coordination of clinical and research activities. In addition, the System and Atlantic Health will share clinical expertise and best practices and coordinate patient care through a common technology platform. The affiliation will afford the System the opportunity to participate as a Tier 1 hospital in Horizon's OMNIA network effective April 1, 2020.

Due to the global viral outbreak caused by Coronavirus Disease 2019 (COVID-19) in 2020, there have been resulting effects which could negatively impact the System's financial condition, including significant stock market exchange volatility, various temporary business closures and event cancellations, decisions to defer elective procedures and other medical treatments at the

Notes to Consolidated Financial Statements (continued)

16. Events Subsequent to December 31, 2019 (continued)

System and other effects which could result in supply chain disruptions. Management continues to closely monitor the impact of COVID-19 in many respects. The ultimate impact of these matters to the System and its financial condition is presently unknown. To enhance liquidity, the System is participating in the Centers for Medicare & Medicaid Services' Accelerated and Advance Payment Program under which it received approximately \$42.7 million in April 2020 in expedited payments for future services. This advance payment amount will be recouped over time as Medicare services are provided after a 120-day delay period, with a final repayment of any remaining balance due in April 2021. The System also received an initial grant distribution under the Coronavirus Aid, Relief, and Economic Security (CARES) Act totaling \$5.5 million in April 2020. The accompanying consolidated financial statements as of and for the year ended December 31, 2019 do not reflect the effects of these subsequent events.



Consolidating Balance Sheet

December 31, 2019 (With Comparative Consolidated Amounts at December 31, 2018) (In Thousands)

		CentraState Healthcare Services, Inc.										_											
	CentraState CentraState Healthcare Medical System, Inc. Center, Inc.		Healthcare Medical			Center · Aging,	CentraState Healthcare Affiliates,	CentraState Assisted	:	CentraState Healthcare Foundation,	CentraState Healthcare Services,	CentraState Medical Arts Building			CentraState Healthcare Services, Inc. Consolidated		CentraState Medical		entraState			 CentraSta Healthcare Syst Consolidated	tem, Inc. l Total
			C	Center, Inc.		Inc.	Inc.	Living, Inc.		Inc.	Inc.	LLC	Eliminati	ons	Total	As	ssociates, P.C.	Spec	cialists, P.C.	Eli	minations	2019	2018
Assets																							
Current assets:																							
Cash and cash equivalents	\$	37	\$	12,029	\$	2,445	\$ 957	\$ 55		1,127	\$ 629	\$ 513	\$	-	\$ 1,142	\$	340	\$	191	\$	_	\$ 18,824 \$	24,098
Short-term investments		_		126,895		27,766	9,966	29	6	_	_	_		-	_		_		_		_	164,923	150,625
Assets limited as to use that are required																							
for current liabilities		-		536		_	_		_	558	_	_		-	_		_		_		_	1,094	1,036
Patient accounts receivable, net		-		26,151		461	1,282	14	6	_	_	_		-	_		501		324		_	28,865	26,349
Due from affiliates		_		4,595		_	_		_	_	_	_		_	_		_		_		(4,595)	_	_
Other current assets		_		16,073		916	405	4	7	1,624	256	_		-	256		158		60		_	19,539	11,663
Total current assets		37		186,279		31,588	12,610	1,04	5	3,309	885	513		-	1,398		999		575		(4,595)	233,245	213,771
Assets limited as to use – noncurrent		_		12,318		3,118	_		_	13,951	_	_		_	_		_		_		_	29,387	28,207
Due from affiliates – noncurrent		-		8,146		_	_		_	_	1,483	2,918		-	4,401		_		_		(12,547)	_	_
Investment in subsidiary		-		_		_	_		_	_	3,861	_	(3,	861)	_		_		_		_	_	_
Interest in CentraState Healthcare Foundation		_		16,412		3,594	87		2	_	_	_		_	_		_		_		(20,095)	_	_
Property, plant, and equipment, net		-		123,708		50,303	3,080	5,96	3	72	3,661	7,098		-	10,759		122		113		_	194,120	189,613
Operating lease assets		_		6,472		_	_		_	_	7,511	_		_	7,511		_		_		_	13,983	_
Noncurrent assets		_		16,055		-	_		_	869	1,792	_		_	1,792		(241)		_		(4,892)	13,583	3,428
	\$	37	\$	369,390	\$	88,603	\$ 15,777	\$ 7,01	0 \$	18,201	\$ 19,193	\$ 10,529	\$ (3,	861)	\$ 25,861	\$	880	\$	688	\$	(42,129)	\$ 484,318 \$	435,019

Consolidating Balance Sheet (continued)

December 31, 2019 (With Comparative Consolidated Amounts at December 31, 2018) (In Thousands)

								CentraState Healtl	hcare Services, Inc.						
	CentraState Healthcare System, Inc.	CentraState Medical Center, Inc.	Center for Aging, Inc.	CentraState Healthcare Affiliates, Inc.	CentraState Assisted Living, Inc.	CentraState Healthcare Foundation, Inc.	CentraState Healthcare Services, Inc.	CentraState Medical Arts Building LLC	Eliminations	CentraState Healthcare Services, Inc. Consolidated Total	CentraState Medical Associates, P.C.	CentraState Specialists, P.C.	Eliminations _	CentraSt Healthcare Sys Consolidated	tem, Inc.
Liabilities and net assets	System, mer	- Contert, met			21,1119,1110			220	231111111111111111111111111111111111111	10111	11550011105,1101	Specialists, Free	231111111111111111111111111111111111111	2012	2010
Current liabilities:															
Current maturities of long-term debt and															
finance lease obligations	\$ -	\$ 5,005	\$ 1.045	\$ -	\$ -	\$ - 5		\$ 775	\$ -	\$ 775	S –	\$ -	\$ -	\$ 6,825 \$	6,635
Accounts payable and accrued expenses	_	27.002	1,569	1,347	487	209	136	233	_	369	467	365	_	41,906	38,487
Due to affiliates – current	_		463	400	193	4	3,273		_	3,273	_	262	(4,595)	_	_
Estimated third-party payer settlements,						•	-,			-,			(1,277)		
current	_	3,235	_	_	_	_	_	_	_	_	_	_	_	3,235	1,287
Operating lease liability – current	_	1,125	_	_	_	_	493	_	_	493	_	_	_	1,618	
Other current liabilities	_		234	44	_	60	_	_	_	_	_	_	_	338	320
Total current liabilities	_	46,458	3,311	1,791	680	273	3,902	1,008	_	4,910	467	627	(4,595)	53,922	46,729
Long-term debt and finance lease obligations,															
excluding current installments	_	86,764	20,609	_	_	_	_	4,857	_	4,857	_	_	_	112,230	118,985
Due to affiliates – non-current	_	2,918	_	_	3,156	_	4,990	_	_	4,990	1,483	_	(12,547)	_	_
Professional liability insurance and other		ŕ			· ·		ŕ			ŕ	ŕ		` ' '		
noncurrent liabilities	_	5,697	_	_	_	_	_	_	_	_	_	_	_	5,697	7,736
Estimated third-party payer settlement –															
noncurrent	_	2,585	111	_	31	_	_	_	_	_	_	_	_	2,727	3,069
Operating lease liability – noncurrent	_	5,347	_	_	_	_	7,018	_	_	7,018	_	_	_	12,365	_
Deferred revenue and refundable advance fees			51,982	_	_	_	_	_	_	_	_	_	(4,892)	47,090	46,428
Total liabilities	_	149,769	76,013	1,791	3,867	273	15,910	5,865	_	21,775	1,950	627	(22,034)	234,031	222,947
Commitments and contingencies															
Net assets:															
Without donor restrictions	37	203,209	8,996	13,899	3,141	(2,167)	3,283	4,664	(3,861)	4,086	(1,070)	61	_	230,192	195,743
With donor restrictions	_	16 110	3,594	87	2	20,095	_	_	_	_	_	_	(20,095)	20,095	16,329
Total net assets	37	219,621	12,590	13,986	3,143	17,928	3,283	4,664	(3,861)	4,086	(1,070)	61	(20,095)	250,287	212,072
_	\$ 37	\$ 369,390	\$ 88,603	\$ 15,777	\$ 7,010	\$ 18,201	19,193	\$ 10,529	\$ (3,861)	\$ 25,861	\$ 880	\$ 688	\$ (42,129)	\$ 484,318 \$	435,019

Consolidating Statement of Operations

Year Ended December 31, 2019 (With Comparative Consolidated Amounts for the Year Ended December 31, 2018) (In Thousands)

									CentraState Healt	thcare Services, Inc	:.					
	CentraStat Healthcare	e	entraState Medical	Center for Aging,	CentraState Healthcare Affiliates,	CentraState Assisted	CentraState Healthcare Foundation,	CentraState Healthcare Services,	CentraState Medical Arts Building		CentraState Healthcare Services, Inc. Consolidated	CentraState Medical	CentraState		CentraSta Healthcare Syst Consolidated	tem, Inc. Total
Revenue:	System, Inc	c. C	Center, Inc.	Inc.	Inc.	Living, Inc.	Inc.	Inc.	LLC	Eliminations	Total	Associates, P.C.	Specialists, P.C.	Eliminations	2019	2018
	Φ.	•	202 (27		n 12 222	Φ.	Φ. Φ.		0	Φ.	•	Φ 2.072	0 1 104		211.057	202.267
Net patient service revenue	\$	- \$	2,0,02,	\$ -	\$ 13,333		\$ - \$		\$ -	\$ -	\$ -	\$ 3,873	\$ 1,124	\$ - \$	311,957 \$	293,367
Other revenue		_	10,553	24,780	343	5,931	_	1,785	1,542	_	3,327	4,064	1,905	(6,228)	44,675	42,660
Investment return			7,492	1,748	365	- 9	<u>l</u>	2,426	1	_	2,427	(138)	_	(392)	11,512	18,937
Total revenue		_	311,672	26,528	14,041	5,940	1	4,211	1,543	_	5,754	7,799	3,029	(6,620)	368,144	354,964
Expenses:																
Salaries and wages		_	114,855	8,674	6,401	2,959	_	_	_	_	_	4,514	1,499	_	138,902	135,054
Employee benefits		_	30,475	2,653	1,986	1,032	_	_	_	_	_	906	268	_	37,320	38,204
Professional fees		_	8,097	_	_	_	_	_	_	_	_	_	_	_	8,097	7,409
Supplies and other expenses		_	123,969	8,814	4,934	1,282	1,253	5,013	468	_	5,481	(544)	1,253	(6,228)	140,214	134,710
Depreciation and amortization		_	13,458	2,945	496	487	29	391	318	_	709	22	9	_	18,155	17,988
Interest expense and amortization																
of financing costs		_	3,059	624	_	92	_	330	297	_	627	107	_	(392)	4,117	4,571
Total expenses		_	293,913	23,710	13,817	5,852	1,282	5,734	1,083	_	6,817	5,005	3,029	(6,620)	346,805	337,936
Income (loss) from operations		-	17,759	2,818	224	88	(1,281)	(1,523)	460	-	(1,063)	2,794	-	_	21,339	17,028
Net change in unrealized gains and losses																
on investments		_	9,019	2,291	891	1	4	_	_	_	_	_	_	-	12,206	(16,905)
Excess (deficiency) of revenue over expenses		-	26,778	5,109	1,115	89	(1,277)	(1,523)	460	-	(1,063)	2,794		-	33,545	123
Equity transfer Net assets released from restrictions for		_	(4,755)	_	-	_	4,755	_	_	_	-	_	-	-	-	_
capital purposes		_	881	4	8	11	_	_	_	_	_	_	_	_	904	1,170
Change in net assets without donor																· · · · · · · · · · · · · · · · · · ·
restrictions	\$	- \$	22,904	\$ 5,113	\$ 1,123	\$ 100	\$ 3,478	\$ (1,523)	\$ 460	\$ -	\$ (1,063)	\$ 2,794	\$ -	\$ - \$	34,449 \$	1,293

Consolidating Statement of Changes in Net Assets

Year Ended December 31, 2019 (With Comparative Consolidated Amounts for the Year Ended December 31, 2018) (In Thousands)

													CentraState Healthcare Services, Inc.															
		ntraState ealthcare		entraState Medical	Cen	ter for Aging,	Н	ntraState ealthcare ffiliates,		CentraState Assisted	Н	entraState lealthcare oundation,	Н	entraState Iealthcare Services,		CentraState Medical Arts Building			S	CentraState Healthcare ervices, Inc. Consolidated		traState Medical		CentraState			 Healthcare Consolid	m, Inc. otal
	Sys	stem, Inc.	C	enter, Inc.		Inc.		Inc.	I	Living, Inc.		Inc.		Inc.		LLC	Eli	minations		Total	A	ssociates, P.C.	Sı	pecialists, P.C.	El	iminations	2019	2018
Without Donor Restrictions Net assets as of beginning of year Change in net assets without donor restrictions	\$	37	\$	180,305 22,904	\$	3,883 5,113	\$	12,7 1,1	76 \$ 23	3,041 100	\$	(5,645) 3,478	\$	4,806 (1,523)	\$	4,204 460	\$	(3,861)	\$	5,149 (1,063)	\$	(3,864) 2,794	\$	61	\$	_ _	\$ 195,743 34,449	\$ 194,450 1,293
Net assets as of end of year	\$	37	\$	203,209	\$	8,996		\$ 13,8	99 \$	3,141	\$	(2,167)	\$	3,283	\$	4,664	\$	(3,861)	\$	4,086	\$	(1,070)	\$	61	\$	_	\$ 230,192	\$ 195,743
With Donor Restrictions Net assets as of beginning of year Change in beneficial interest in CentraState Healthcare Foundation, Inc.	\$	-	\$	12,833 3,579	\$	3,387 207	\$	88	\$	11 (9)	\$	16,329	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	(16,319) (3,776)	\$ 16,329	\$ 16,626
Contributions, investment return and other		_		_		_		_		_		5,518		_		_		_		_		_		_			5,518	1,676
Net assets released from restrictions used for operations Net assets released from restrictions for		_		_		-		-		_		(848)		-		-		_		-		-		-		-	(848)	(803)
capital purposes		_		_		_		_		_		(904)		_		_		-		_		_		_		_	(904)	(1,170)
Change in net assets with donor restrictions		_	•	3,579		207		(1)		(9)		3,766		_		_		_		_		_		_		(3,776)	3,766	(297)
Net assets as of end of year	\$	-	\$	16,412	\$	3,594	\$	87	\$	2	\$	20,095	\$	_	\$	_	\$	_	\$	_	\$	_	\$	_	\$	(20,095)	\$ 20,095	\$ 16,329

EY | Assurance | Tax | Transactions | Advisory

About EY

EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.

© 2020 Ernst & Young LLP. All Rights Reserved.

ey.com